Form 8-K - Current report:
SEC Accession No. 0001493152-23-002354
Filing Date
2023-01-24
Accepted
2023-01-24 17:17:06
Documents
15
Period of Report
2023-01-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41643
2 ex99-1.htm EX-99.1 29166
3 ex99-1_001.jpg GRAPHIC 11458
  Complete submission text file 0001493152-23-002354.txt   310095

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bct-20230124.xsd EX-101.SCH 3949
5 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bct-20230124_def.xml EX-101.DEF 26582
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bct-20230124_lab.xml EX-101.LAB 36619
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bct-20230124_pre.xml EX-101.PRE 25206
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5426
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 23549010
SIC: 2834 Pharmaceutical Preparations